Neurology, Bispebjerg Hospital, Copenhagen, Denmark.
Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
J Neurol Neurosurg Psychiatry. 2020 Dec;91(12):1261-1269. doi: 10.1136/jnnp-2020-323141. Epub 2020 Oct 21.
Functional movement disorders (FMD) are proposed to reflect a specific problem with voluntary control of movement, despite normal intent to move and an intact neural capacity for movement. In many cases, a positive diagnosis of FMD can be established on clinical grounds. However, the diagnosis remains challenging in certain scenarios, and there is a need for predictors of treatment response and long-term prognosis.In this context, we performed a systematic review of biomarkers in FMD. Eighty-six studies met our predefined criteria and were included.We found fairly reliable electroencephalography and electromyography-based diagnostic biomarkers for functional myoclonus and tremor. Promising biomarkers have also been described for functional paresis, gait and balance disorders. In contrast, there is still a lack of diagnostic biomarkers of functional dystonia and tics, where clinical diagnosis is often also more challenging. Importantly, many promising findings focus on pathophysiology and reflect group-level comparisons, but cannot differentiate on an individual basis. Some biomarkers also require access to time-consuming and resource-consuming techniques such as functional MRI.In conclusion, there are important gaps in diagnostic biomarkers in FMD in the areas of most clinical uncertainty. There is also is a lack of treatment response and prognostic biomarkers to aid in the selection of patients who would benefit from rehabilitation and other forms of treatment.
功能性运动障碍(FMD)被认为反映了运动的自愿控制方面的特定问题,尽管有移动的正常意图和运动的完整神经能力。在许多情况下,可以基于临床依据明确诊断 FMD。然而,在某些情况下,诊断仍然具有挑战性,并且需要治疗反应和长期预后的预测因子。在这种情况下,我们对 FMD 的生物标志物进行了系统评价。符合我们预定义标准的 86 项研究被纳入。我们发现,功能性肌阵挛和震颤有相当可靠的基于脑电图和肌电图的诊断生物标志物。功能性瘫痪、步态和平衡障碍也有有前途的生物标志物。相比之下,功能性肌张力障碍和抽动障碍的诊断生物标志物仍然缺乏,在这些情况下,临床诊断通常也更具挑战性。重要的是,许多有前途的发现集中在病理生理学上,反映了组水平的比较,但不能在个体基础上进行区分。一些生物标志物还需要使用功能磁共振成像等耗时且资源密集的技术。总之,在最不确定的临床领域,FMD 的诊断生物标志物存在重要差距。也缺乏治疗反应和预后生物标志物来帮助选择受益于康复和其他治疗形式的患者。